Skip to main content
. 2023 Jul 15;30:333–349. doi: 10.1016/j.omtm.2023.07.005

Figure 3.

Figure 3

Improvement of neurological score, motor function, and cognitive function by administration of BMMSCs and iMSCs

(A and B) Abnormal posture (A) and hemiparesis (B) assessment 3, 7, 14, 28, and 56 days after tMCAO in vehicle-, BMMSC-, and iMSC-transplanted reperfusion groups. Boxplots indicate the median and IQR, and whiskers indicate the maximum and minimum values (∗p < 0.05, ∗∗p < 0.01; n = 8 for each group). (C and D) Rotarod performance (C) and forelimb grip strength (D) assessment 3, 7, 14, 28, and 56 days after tMCAO in vehicle-, BMMSC-, and iMSC-transplanted reperfusion groups. Data are presented as mean ± SD (∗p < 0.05, ∗∗p < 0.01; n = 8 for each group). (E) Improvement of spatial working memory 28 and 56 days after tMCAO. Shown is the alternation rate in the Y-maze spontaneous test in the vehicle-, BMMSC-, and iMSC-treated groups. Data are presented as mean ± SD (∗p < 0.05, ∗∗p < 0.01; n = 8 for each group).